Dyne Therapeutics Reports Wider Net Loss in Third Quarter
The company said higher research and development and general and administrative expenses contributed to the wider year-over-year net loss. The headline lists EPS of ($1.06).
The company said higher research and development and general and administrative expenses contributed to the wider year-over-year net loss. The headline lists EPS of ($1.06).